Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

  • STATUS
    Recruiting
  • End date
    Oct 30, 2025
  • participants needed
    238
  • sponsor
    wang, jianxiang
Updated on 17 October 2021

Summary

Compared with patients with philadelphia chromosome-negative Acute Lymphoblastic Leukemia (Ph- ALL), patients with Ph-positive (Ph+) ALL exhibit a comparatively poor prognosis. Fortunately, significant improvements have been found in response rates, disease-free survival (DFS), and overall survival (OS) for patients with Ph+ ALL with the introduction of tyrosine kinase inhibitor (TKI) therapy to treatment regimens. Based on improvements in efficacy and tolerability, next-generation TKIs have been widely used in first-line treatment for chronic myeloid leukemia (CML). Flumatinib, a TKI with more potent binding affinity for BCR-ABL1 tyrosine kinase than imatinib, demonstrated higher rates of responses, faster and deeper responses in FESTnd trial, which suggested that flumatinib might show improved clinical efficacy for treating Ph+ ALL compared with imatinib. The investigators therefore hypothesized that the addition of flumatinib to combinatorial chemotherapy regimen would demonstrate greater efficacy compared with the prior use of imatinib in treating Ph+ ALL. This study explored the safety and efficacy of flumatinib versus imatinib when combined with multi-agent chemotherapy in patients with newly diagnosed Ph+ ALL.

Details
Condition Acute Leukemia, acute leukemias
Treatment Imatinib, Flumatinib
Clinical Study IdentifierNCT05071482
Sponsorwang, jianxiang
Last Modified on17 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients aged 18 to 65 years, male or female
Newly diagnosed Philadelphia chromosome positive(either t(9;22) and/or BCR-ABL positive and/ or FISH positive) acute lymphoblastic leukemia; Patients will be diagnosed according to morphologic,immunologic, cytogenetic and molecular(MICM) criteria, including bone marrow morphology, immunophenotype, cytogenetic and molecular genetic (BCR/ABL gene, qualitative and quantitative analysis) examination
Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
Adequate end organ function as defined by: Total bilirubin 1.5 x upper limit of normalULN; serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) 2.5 x ULN or 5 x ULN if leukemic involvement of the liver is present; Creatinine 1.5 x ULN; Serum amylase and lipase 1.5 x ULN; Alkaline phosphatase 2.5 x ULN unless considered tumor related; normal electrolytes: Potassium LLN; Magnesium LLN; Phosphorus LLN
Cardiac color Doppler ultrasound ejection fraction 45%
Subject has provided written informed consent prior to any screening procedure

Exclusion Criteria

Lymphoid blast crisis of chronic myelocytic leukemia (CML)
Previous or ongoing systemic anti-ALL therapy (including but not restricted to TKI and/or radiotherapy, except for appropriate pre-treatment)
Patients with clinical manifestations of central or extramedullary invasion of leukemia at diagnosis
Identification of T315I mutation
Concurrent participation in another clinical study with an investigational medical product
Any concurrent severe and/or uncontrolled medical condition, which could, in the opinion of the investigator, compromise participation in the study
History of neurological or psychiatric disorders, including epilepsy or dementia
Major surgery within 4 weeks or failure to recover from previous surgery
Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
Female patients who are pregnant or breast feeding or patients of childbearing potential and male patients whose sexual partner(s) are women of childbearing potential not willing to use a highly effective method of contraception
Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to: any history of myocardial infarction, stroke, or revascularization; unstable angina or transient ischemic attack within 6 months prior to enrolment; congestive heart failure within 6 months prior to enrolment or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards; history of clinically significant (as determined by the treating physician) atrial arrhythmia; any history of ventricular arrhythmia; any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism;Uncontrolled hypertension
Active known positive HIV serology
Active serious infection not controlled by oral or intravenous antibiotics
Patients with known allergies or contraindications to the study drug
Patients with bleeding disorders unrelated to ALL
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note